Cardiovascular Drugs Practice Questions

Q: Which drug is NOT useful in congestive heart failure?

Adrenaline. **Explanation:** In Congestive Heart Failure (CHF), the primary goal is to improve cardiac output while reducing the workload on an already failing heart. **Why Adrenaline (Option A) is the correct answer:** Adrenaline is a potent non-selective alpha and beta-adrenergic agonist. While it increases myocardial contractility (positive inotropy), it significantly increases heart rate (positive chronotropy) and peripheral vascular resistance. This leads to a massive increase in **myocardial oxygen demand** and **afterload**, which can precipitate arrhythmias and worsen myocardial ischemia in a failing heart. Therefore, it has no role in the long-term management of CHF. **Why the other options are used in CHF:** * **Digoxin (Option B):** A cardiac glycoside that inhibits the Na+/K+ ATPase pump, increasing intracellular calcium. It provides **positive inotropic** support and controls heart rate (especially in patients with concomitant Atrial Fibrillation). * **Hydrochlorothiazide (Option C):** A thiazide diuretic used to reduce fluid overload (preload), thereby relieving symptoms of pulmonary and peripheral edema. * **Enalapril (Option D):** An ACE inhibitor that is a cornerstone of CHF therapy. It reduces both **preload and afterload** and, most importantly, inhibits cardiac remodeling, which reduces mortality. **High-Yield Clinical Pearls for NEET-PG:** * **Mortality Benefit:** ACE inhibitors (Enalapril), Beta-blockers (Carvedilol, Metoprolol), Spironolactone, and ARNIs (Sacubitril/Valsartan) are proven to decrease mortality in CHF. * **Symptomatic Relief Only:** Digoxin and Diuretics improve symptoms and reduce hospitalizations but do **not** decrease mortality. * **Inotropic Support:** For acute decompensated heart failure, **Dobutamine** or **Milrinone** are preferred over Adrenaline as they are less likely to cause extreme tachycardia and vasoconstriction.

Q: Which of the following antihypertensive drugs is contraindicated in the treatment of hypertension during pregnancy?

Captopril. The correct answer is **Captopril (Option B)**. Captopril is an **ACE Inhibitor (ACEI)**. ACE inhibitors and Angiotensin Receptor Blockers (ARBs) are strictly contraindicated throughout pregnancy (FDA Category D) [1, 2]. The underlying medical concept is their **teratogenic potential**, particularly during the second and third trimesters [1, 2]. They interfere with fetal renal development, leading to **fetal renal dysgenesis**, oligohydramnios, pulmonary hypoplasia, intrauterine growth restriction (IUGR), and cranial ossification defects [1, 2]. **Why the other options are incorrect:** * **Methyldopa (Option C):** Historically the drug of choice for chronic hypertension in pregnancy. It is a centrally acting alpha-2 agonist with a long-standing safety profile. * **Hydralazine (Option D):** A direct vasodilator frequently used parenterally for the management of hypertensive emergencies in pregnancy (Preeclampsia/Eclampsia). * **Nifedipine (Option A):** A Calcium Channel Blocker (CCB) commonly used as an oral maintenance therapy for hypertension in pregnancy. **NEET-PG High-Yield Pearls:** 1. **Drugs of Choice in Pregnancy:** Labetalol (often considered first-line now), Methyldopa, and Nifedipine. 2. **Teratogenic effect of ACEIs:** "Potter-like syndrome" due to oligohydramnios. 3. **Diuretics:** Generally avoided in pregnancy as they can prevent the physiological expansion of maternal plasma volume. 4. **Sodium Nitroprusside:** Avoided in pregnancy due to the risk of fetal cyanide poisoning.

Q: In a patient with hypertriglyceridemia and low HDL, which of the following drugs will not increase the risk of myopathy?

Nicotinic acid. **Explanation:** The core concept tested here is the **risk of myopathy (rhabdomyolysis)** associated with lipid-lowering agents, particularly when used in combination. **Why Nicotinic Acid (Niacin) is the correct answer:** Nicotinic acid is highly effective for increasing HDL and lowering triglycerides. Unlike statins and fibrates, it does not significantly interfere with the metabolic pathways of muscle cells or the glucuronidation of other lipid drugs. While it has side effects like flushing and dyspepsia, it does **not** inherently increase the risk of myopathy when used as monotherapy or significantly potentiate statin-induced myopathy compared to fibrates. **Why the other options are incorrect:** * **Atorvastatin & Lovastatin (Options C & D):** Statins inhibit HMG-CoA reductase. A well-known adverse effect is **statin-associated muscle symptoms (SAMS)**, ranging from myalgia to life-threatening rhabdomyolysis. This occurs due to decreased production of Coenzyme Q10 and isoprenoids in muscle cells. * **Fibric acid derivatives (Option A):** Fibrates (especially Gemfibrozil) are notorious for causing myopathy. They inhibit the glucuronidation of statins, leading to increased statin plasma levels. Combining a fibrate with a statin exponentially increases the risk of muscle toxicity. **High-Yield Clinical Pearls for NEET-PG:** 1. **Gemfibrozil vs. Fenofibrate:** If a fibrate must be combined with a statin, **Fenofibrate** is preferred over Gemfibrozil because it does not inhibit statin metabolism as aggressively. 2. **Monitoring:** Always check **Creatine Kinase (CK)** levels in patients on statins who complain of muscle pain or weakness. 3. **Niacin Side Effect:** The most common side effect is cutaneous flushing, mediated by **Prostaglandin D2**, which can be blunted by taking **Aspirin** 30 minutes prior.

Q: What is the best time to administer long-term nitrates for nocturnal angina?

Evening. **Explanation:** The primary goal in administering long-term nitrates (like Isosorbide mononitrate or dinitrate) is to provide therapeutic coverage during the period of maximum symptoms while preventing **nitrate tolerance**. **1. Why Evening is Correct:** For patients with **nocturnal angina**, symptoms occur during sleep. Administering the dose in the **evening** ensures peak plasma concentrations during the night. More importantly, this schedule allows for a **"nitrate-free interval"** of 10–12 hours during the day. This interval is essential to restore the sulfhydryl groups required for nitric oxide production, thereby preventing the development of tolerance. **2. Analysis of Incorrect Options:** * **Early morning (A) & Noon (B):** These timings are appropriate for patients with *exertional angina* (angina of effort) to provide coverage during daytime activities. However, for nocturnal angina, the drug levels would be too low by nighttime to be effective. * **Late night (D):** While this provides coverage for the night, it shifts the nitrate-free interval into the late afternoon/evening, which may not be as physiologically optimal as an evening dose for preventing tolerance while maintaining nocturnal efficacy. **3. High-Yield NEET-PG Pearls:** * **Nitrate Tolerance:** Occurs due to the depletion of free sulfhydryl groups and "oxidative stress." It is best prevented by a daily nitrate-free interval of **at least 10–12 hours**. * **Drug of Choice:** For *acute* episodes of any angina, Sublingual Nitroglycerin is used. For *prophylaxis* of nocturnal angina, evening administration of long-acting nitrates is preferred. * **Contraindication:** Never co-administer nitrates with **Sildenafil** (PDE-5 inhibitors) as it can lead to severe, life-threatening hypotension.

Q: Compared to digoxin, what is a characteristic of digitoxin?

Longer plasma half-life. **Explanation:** The primary difference between Digoxin and Digitoxin lies in their lipid solubility. **Digitoxin** is highly lipid-soluble (non-polar), whereas Digoxin is relatively polar. **Why the correct answer is right:** Because Digitoxin is highly lipid-soluble, it undergoes extensive **enterohepatic circulation** and is heavily bound to plasma proteins. This results in a significantly **longer plasma half-life** (approximately 5–7 days) compared to Digoxin (approximately 36–40 hours). This long half-life means Digitoxin takes much longer to reach a steady state and longer to be eliminated from the body once discontinued. **Analysis of Incorrect Options:** * **A. Less plasma protein binding:** Incorrect. Digitoxin has very high protein binding (~95%), whereas Digoxin has low binding (~25%). * **C. Less oral absorption:** Incorrect. Due to its lipid solubility, Digitoxin is almost 100% absorbed from the gut. Digoxin absorption is variable (60–80%). * **D. More daily elimination:** Incorrect. Digitoxin has a lower daily elimination rate (~10%) compared to Digoxin (~33%) because of its long half-life and extensive reabsorption. **NEET-PG High-Yield Pearls:** * **Route of Elimination:** Digoxin is primarily excreted **renally** (unchanged), making it contraindicated in renal failure. Digitoxin is primarily metabolized by the **liver**, making it the preferred cardiac glycoside in patients with renal impairment. * **Volume of Distribution:** Digoxin has a very high $V_d$ because it binds strongly to skeletal muscle (Na+/K+ ATPase). * **Toxicity:** Hypokalemia predisposes to digoxin toxicity because K+ and digoxin compete for the same binding site on the Na+/K+ ATPase pump.

Q: Ezetimibe acts on which of the following targets?

Niemann-Pick C1-Like 1 (NPC1L1) protein. **Explanation:** **Mechanism of Action (Why C is correct):** Ezetimibe is a lipid-lowering agent that selectively inhibits the intestinal absorption of cholesterol and related phytosterols [1]. It specifically targets and binds to the **Niemann-Pick C1-Like 1 (NPC1L1) protein**, a transport protein located on the brush border membrane of enterocytes in the small intestine [2]. By blocking this transporter, Ezetimibe reduces the delivery of intestinal cholesterol to the liver, leading to a compensatory increase in LDL-receptor expression and a subsequent decrease in circulating LDL-C levels [1]. **Analysis of Incorrect Options:** * **A. Lipoprotein lipase (LPL):** This enzyme is activated by **Fibrates** (via PPAR-α) to increase the clearance of triglyceride-rich lipoproteins [5]. * **B. Peroxisome proliferator-activated receptor (PPAR):** PPAR-α is the target for **Fibrates** (e.g., Fenofibrate), while PPAR-γ is the target for **Thiazolidinediones** (e.g., Pioglitazone). * **D. HMG-CoA reductase:** This is the rate-limiting enzyme in hepatic cholesterol synthesis, which is inhibited by **Statins** [3], [4]. **High-Yield Clinical Pearls for NEET-PG:** * **Synergy:** Ezetimibe is frequently used as an "add-on" therapy to Statins. While Statins inhibit cholesterol *synthesis*, Ezetimibe inhibits cholesterol *absorption* (Dual inhibition) [1]. * **Effect on Lipids:** Its primary effect is a 15–20% reduction in **LDL**. It has minimal effects on HDL or Triglycerides [1]. * **Side Effects:** Generally well-tolerated; however, it may cause increased hepatic transaminases when used with statins. * **Vytorin:** A fixed-dose combination of Ezetimibe + Simvastatin.

Question 1

Which drug is NOT useful in congestive heart failure?

Accepted Answer

Adrenaline

Answer

Digoxin

Answer

Hydrochlorothiazide

Answer

Enalapril

Question 2

Which of the following antihypertensive drugs is contraindicated in the treatment of hypertension during pregnancy?

Accepted Answer

Captopril

Answer

Nifedipine

Answer

Methyldopa

Answer

Hydralazine

Question 3

In a patient with hypertriglyceridemia and low HDL, which of the following drugs will not increase the risk of myopathy?

Accepted Answer

Nicotinic acid

Answer

Fibric acid derivatives

Answer

Atorvastatin

Answer

Lovastatin

Question 4

Which of the following agents decreases preload?

Accepted Answer

Nitroglycerine

Answer

Hydralazine

Answer

Nifedipine

Answer

Losartan

Question 5

A patient is alert and oriented and has a BP of 110/60. In which patient would adenosine constitute appropriate initial therapy?

Accepted Answer

A 65-year-old woman with known ischemic disease and narrow complex tachycardia

Answer

A 65-year-old man with no ischemic heart disease and wide complex tachycardia

Answer

A 25-year-old woman with known preexcitation syndrome and narrow complex tachycardia

Answer

A 28-year-old man with known preexcitation syndrome and wide complex tachycardia

Question 6

What is the best time to administer long-term nitrates for nocturnal angina?

Accepted Answer

Evening

Answer

Early morning

Answer

Noon

Answer

Late night

Question 7

Compared to digoxin, what is a characteristic of digitoxin?

Accepted Answer

Longer plasma half-life

Answer

Less plasma protein binding

Answer

Less oral absorption

Answer

More daily elimination

Question 8

Ezetimibe acts on which of the following targets?

Accepted Answer

Niemann-Pick C1-Like 1 (NPC1L1) protein

Answer

Lipoprotein lipase (LPL)

Answer

Peroxisome proliferator-activated receptor (PPAR)

Answer

HMG-CoA reductase inhibitor

Question 9

Which local anesthetic agent is also used as an antiarrhythmic agent?

Accepted Answer

Lignocaine

Answer

Bupivacaine

Answer

Cocaine

Answer

Chlorprocaine

Question 10

All of the following are useful in the intravenous therapy for hypertensive emergencies except:

Accepted Answer

Fenoldopam

Answer

Urapidil

Answer

Enalaprilat

Answer

Nifedipine

Cardiovascular Drugs — MCQs

Cardiovascular Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?